Larimar Stock: Friedreich’s Ataxia Drug With Significant Potential (NASDAQ:LRMR)


Male scientist working at the laboratory. Cloud up medical hand using micro pipette for test analysis. Scientific Lab for Medicine, Biotechnology Researchers.

Pratchaya/iStock via Getty Images

Larimar therapeutics (NASDAQ:LRMR) has been making significant progress in advancing its drug known as CTI-1601, which is being developed for the treatment of patients with Friedreich’s ataxia [FA]. That’s because it just received clearance from the FDA



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *